Sponsored by:
This activity focuses on new management options with cannabidiol (CBD) and non-intoxicating pharmaceutical cannabis.
Learning outcomes
By the end of this activity, participants will be able to:
- Identify patients with treatment-resistant mental health conditions who may benefit, and are eligible for treatment with cannabidiol (CBD) and CBD-dominant pharmaceutical cannabis
- Discuss the clinical management of patients with treatment-resistant mental health conditions prescribed CBD and CBD-dominant pharmaceutical cannabis including product choice, dosage, titration and duration of treatment
- Describe the available prescribing pathways for CBD and CBD-dominant pharmaceutical cannabis in eligible patients with treatment-resistant mental health conditions.
This education is a CPD-accredited activity under the RACGP CPD Program for the 2020-22 triennium. This activity is designed to take 1 hour to complete.
Other healthcare professionals can still enrol and complete this course. You will receive a certificate upon completion.
START LEARNING
If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.
